Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 12, 2024Journal of Experimental & Clinical Cancer ResearchOpen Access

Synergistic intravesical instillation for bladder cancer: CRISPR-Cas13a and fenbendazole combination therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMingkang LiangYWYongqiang WangLLLisha Liu

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Liang et al. (2024) studied this question.

synapsesocial.com/papers/68e5c976b6db64358755fe84https://doi.org/10.1186/s13046-024-03146-0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fluorinated Chitosan‐Mediated Transepithelial Delivery of Intravesical Dual‐Drug Immunotherapeutic for Bladder Cancer Therapy2024 · 4 citations
  2. 2CRISPR-based gene expression platform for precise regulation of bladder cancer2024 · 5 citations
  3. 3Context-Responsive Nanoparticle Derived from Synthetic Zwitterionic Ionizable Phospholipids in Targeted CRISPR/Cas9 Therapy for Basal-like Breast Cancer2024 · 15 citations
  4. 4Core–Shell Tripeptide-Lipid/PEI Nanocarriers Enable Efficient Plasmid-Based CRISPR/Cas9 Editing of <i>VEGFR2</i>2025
  5. 5Ferroptosis Induction by Fenbendazole Combined With Photothermal Therapy Triggers Dual‐Immunotherapy Against Bladder Cancer2026